Olema Pharma Q3 net loss widens

Olema Pharmaceuticals

10/11/2025 12:15

Overview

Olema reports Q3 net loss of $42.2 mln due to increased R&D expenses

Company ends Q3 with $329 mln in cash and marketable securities

Announced clinical trial agreement with Pfizer for palazestrant and atirmociclib

Outlook

Company to initiate Phase 1b/2 study with Pfizer in Q4 2025

Olema to present trial poster at SABCS in December 2025

Result Drivers

CLINICAL TRIAL AGREEMENT - Announced agreement with Pfizer to evaluate palazestrant with atirmociclib in ER+/HER2- metastatic breast cancer

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$42.22 mln
Q3 Income From Operations
-$45.88 mln
Q3 Operating Expenses
$45.88 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Olema Pharmaceuticals Inc is $22.00, about 62% above its November 7 closing price of $8.35

Press Release: ID:nGNX7YwxkL

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)